The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Add Yahoo as a preferred source to see more of our stories on Google. Global health foundation Coalition for Epidemic Preparedness Innovations (CEPI) will invest $50 million to support development and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Coalition for Epidemic ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A sign marks the offices of Moderna in Cambridge, Massachusetts, U.S., July 22, 2025. REUTERS/Brian Snyder/File Photo ...

Moderna (MRNA) is in the early stages of developing a hantavirus vaccine, though its availability could be years away. Shares are up ~14% in Friday afternoon trading. Hantavirus has received renewed ...

Moderna Inc. said it’s researching vaccines to protect against hantaviruses, even as public health experts downplay the risk the deadly pathogen aboard a cruise ship could become a significant threat.

Moderna's MRNA.O mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and older, researchers reported on ...

The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Subscribe to read this story ad-free Get ...

April 24 (Reuters) - German biotech company CureVac sued Moderna (MRNA.O), opens new tab in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac ...

Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. Moderna will pay $950 million ...